Prophylaxis of migraine: general principles and patient acceptance
- PMID: 19337456
- PMCID: PMC2646645
- DOI: 10.2147/ndt.s3497
Prophylaxis of migraine: general principles and patient acceptance
Abstract
Migraine is a chronic neurological condition with episodic exacerbations. Migraine is highly prevalent, and associated with significant pain, disability, and diminished quality of life. Migraine management is an important health care issue. Migraine management includes avoidance of trigger factors, lifestyle modifications, non-pharmacological therapies, and medications. Pharmacological treatment is traditionally divided into acute or symptomatic treatment, and preventive treatment or prophylaxis. Many migraine patients can be treated using only acute treatment. Patients with severe and/or frequent migraines require long-term preventive therapy. Prophylaxis requires daily administration of anti-migraine compounds with potential adverse events or contraindications, and may also interfere with other concurrent conditions and treatments. These problems may induce patients to reject the idea of a preventive treatment, leading to poor patient adherence. This paper reviews the main factors influencing patient acceptance of anti-migraine prophylaxis, providing practical suggestions to enhance patient willingness to accept pharmacological anti-migraine preventive therapy. We also provide information about the main clinical characteristics of migraine, and their negative consequences. The circumstances warranting prophylaxis in migraine patients as well as the main characteristics of the compounds currently used in migraine prophylaxis will also be briefly discussed, focusing on those aspects which can enhance patient acceptance and adherence.
Keywords: acceptance; adherence; migraine; preventive therapy; prophylaxis.
Similar articles
-
Key points in migraine prophylaxis: patient perspective.Neurol Sci. 2009 May;30 Suppl 1:S39-42. doi: 10.1007/s10072-009-0056-4. Neurol Sci. 2009. PMID: 19415424 Review.
-
2022 Taiwan Guidelines for Preventive Treatment of Migraine.Acta Neurol Taiwan. 2022 Sep 30;31(3):164-202. Acta Neurol Taiwan. 2022. PMID: 36089629
-
Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.Headache. 2021 Mar;61(3):493-499. doi: 10.1111/head.14037. Epub 2020 Dec 21. Headache. 2021. PMID: 33349935 Free PMC article.
-
Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.Headache. 2018 May;58(5):700-714. doi: 10.1111/head.13275. Epub 2018 Feb 15. Headache. 2018. PMID: 29446063
-
Practical use of topiramate for migraine prevention.Headache. 2005 Apr;45 Suppl 1:S66-73. doi: 10.1111/j.1526-4610.2005.4501007.x. Headache. 2005. PMID: 15833092 Review.
Cited by
-
Preventive agents for migraine: focus on the antiepileptic drugs.J Cent Nerv Syst Dis. 2012 Feb 26;4:37-49. doi: 10.4137/JCNSD.S9049. Print 2012. J Cent Nerv Syst Dis. 2012. PMID: 23650466 Free PMC article.
-
Key points in migraine prophylaxis: patient perspective.Neurol Sci. 2009 May;30 Suppl 1:S39-42. doi: 10.1007/s10072-009-0056-4. Neurol Sci. 2009. PMID: 19415424 Review.
-
Usefulness of nutraceuticals in migraine prophylaxis.Neurol Sci. 2017 May;38(Suppl 1):117-120. doi: 10.1007/s10072-017-2901-1. Neurol Sci. 2017. PMID: 28527067 Review.
-
Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.J Headache Pain. 2019 Jun 7;20(1):68. doi: 10.1186/s10194-019-1012-1. J Headache Pain. 2019. PMID: 31174464 Free PMC article.
-
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.Pain Ther. 2020 Jun;9(1):195-215. doi: 10.1007/s40122-020-00159-3. Epub 2020 Mar 28. Pain Ther. 2020. PMID: 32222952 Free PMC article. Review.
References
-
- Ayata C, Jin H, Kudo C, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol. 2006;59:652–61. - PubMed
-
- Bigal ME, Rapoport AM, Lipton RB, et al. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache. 2003;43:336–42. - PubMed
-
- Bigal ME, Lipton RB. Modifiable risk factors for migraine progression (or for chronic daily headaches) – clinical lessons. Headache. 2006;46 (Suppl 3):S144–6. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources